Virtual population pharmacokinetic using physiologically based pharmacokinetic model for evaluating bioequivalence of oral lacidipine formulations in dogs
The aim of the present study was to investigate virtual population pharmacokinetic using physiologically based pharmacokinetic (PBPK) model for evaluating bioequivalence of oral lacidipine formulations in dogs. The dissolution behaviors of three lacidipine formulations including one commercial produ...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2017-01-01
|
| Series: | Asian Journal of Pharmaceutical Sciences |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1818087616300149 |
| _version_ | 1819113654283403264 |
|---|---|
| author | Bin Yang Chunnuan Wu Bin Ji Mingrui Wu Zhonggui He Lei Shang Jin Sun |
| author_facet | Bin Yang Chunnuan Wu Bin Ji Mingrui Wu Zhonggui He Lei Shang Jin Sun |
| author_sort | Bin Yang |
| collection | DOAJ |
| description | The aim of the present study was to investigate virtual population pharmacokinetic using physiologically based pharmacokinetic (PBPK) model for evaluating bioequivalence of oral lacidipine formulations in dogs. The dissolution behaviors of three lacidipine formulations including one commercial product and two self-made amorphous solid dispersions (ASDs) capsules were determined in 0.07% Tween 80 media. A randomized 3-period crossover design in 6 healthy beagle dogs after oral administration of the three formulations at a single dose of 4 mg was conducted. The PBPK modeling was utilized for the virtual bioequivalence study. In vitro dissolution experiment showed that the dissolution behaviors of lacidipine amorphous solid dispersions (ASDs) capsules, which was respectively prepared by HPMC-E5 or Soluplus, as polymer displayed similar curves compared with the reference formulation in 0.07% Tween 80 media. In vivo pharmacokinetics experiments showed that three formulations had comparable maximum plasma drug concentration (Cmax), and the time (Tmax) to reach Cmax of lacidipine tablet, which was prepared by Soluplus, as polymer was slower than other two formulations in consistency with the in vitro dissolution rate. The 90% confidence interval (CI) for the Cmax, AUC0–24 h and AUC0–∞ of the ratio of the test drug to the referencedrug exceeded the acceptable bioequivalence (BE) limits (0.80–1.25). However, the 90% CI of the AUC0–24 h, AUC0–∞ and Cmax of the ratio of test to reference drug were within the BE limit, calculated using PBPK modeling when the virtual subjects reached 24 dogs. The results all demonstrated that virtual bioequivalence study can overcome the inequivalence caused by inter-subject variability of the 6 beagle dogs involved in in vivo experiments. |
| first_indexed | 2024-12-22T04:32:50Z |
| format | Article |
| id | doaj.art-b1a0082490aa4aa7bcbefe6a330a5814 |
| institution | Directory Open Access Journal |
| issn | 1818-0876 |
| language | English |
| last_indexed | 2024-12-22T04:32:50Z |
| publishDate | 2017-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Asian Journal of Pharmaceutical Sciences |
| spelling | doaj.art-b1a0082490aa4aa7bcbefe6a330a58142022-12-21T18:38:58ZengElsevierAsian Journal of Pharmaceutical Sciences1818-08762017-01-011219810410.1016/j.ajps.2016.03.003Virtual population pharmacokinetic using physiologically based pharmacokinetic model for evaluating bioequivalence of oral lacidipine formulations in dogsBin Yang0Chunnuan Wu1Bin Ji2Mingrui Wu3Zhonggui He4Lei Shang5Jin Sun6Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, ChinaDepartment of Pharmacy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, ChinaDepartment of Pharmaceutical analysis, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, ChinaDepartment of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, ChinaDepartment of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, ChinaSchool of Pharmacy, China Medical University, Shenyang, ChinaDepartment of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, ChinaThe aim of the present study was to investigate virtual population pharmacokinetic using physiologically based pharmacokinetic (PBPK) model for evaluating bioequivalence of oral lacidipine formulations in dogs. The dissolution behaviors of three lacidipine formulations including one commercial product and two self-made amorphous solid dispersions (ASDs) capsules were determined in 0.07% Tween 80 media. A randomized 3-period crossover design in 6 healthy beagle dogs after oral administration of the three formulations at a single dose of 4 mg was conducted. The PBPK modeling was utilized for the virtual bioequivalence study. In vitro dissolution experiment showed that the dissolution behaviors of lacidipine amorphous solid dispersions (ASDs) capsules, which was respectively prepared by HPMC-E5 or Soluplus, as polymer displayed similar curves compared with the reference formulation in 0.07% Tween 80 media. In vivo pharmacokinetics experiments showed that three formulations had comparable maximum plasma drug concentration (Cmax), and the time (Tmax) to reach Cmax of lacidipine tablet, which was prepared by Soluplus, as polymer was slower than other two formulations in consistency with the in vitro dissolution rate. The 90% confidence interval (CI) for the Cmax, AUC0–24 h and AUC0–∞ of the ratio of the test drug to the referencedrug exceeded the acceptable bioequivalence (BE) limits (0.80–1.25). However, the 90% CI of the AUC0–24 h, AUC0–∞ and Cmax of the ratio of test to reference drug were within the BE limit, calculated using PBPK modeling when the virtual subjects reached 24 dogs. The results all demonstrated that virtual bioequivalence study can overcome the inequivalence caused by inter-subject variability of the 6 beagle dogs involved in in vivo experiments.http://www.sciencedirect.com/science/article/pii/S1818087616300149Physiologically based pharmacokinetic modelVirtual population pharmacokineticBioequivalenceLacidipineAmorphous solid dispersions |
| spellingShingle | Bin Yang Chunnuan Wu Bin Ji Mingrui Wu Zhonggui He Lei Shang Jin Sun Virtual population pharmacokinetic using physiologically based pharmacokinetic model for evaluating bioequivalence of oral lacidipine formulations in dogs Asian Journal of Pharmaceutical Sciences Physiologically based pharmacokinetic model Virtual population pharmacokinetic Bioequivalence Lacidipine Amorphous solid dispersions |
| title | Virtual population pharmacokinetic using physiologically based pharmacokinetic model for evaluating bioequivalence of oral lacidipine formulations in dogs |
| title_full | Virtual population pharmacokinetic using physiologically based pharmacokinetic model for evaluating bioequivalence of oral lacidipine formulations in dogs |
| title_fullStr | Virtual population pharmacokinetic using physiologically based pharmacokinetic model for evaluating bioequivalence of oral lacidipine formulations in dogs |
| title_full_unstemmed | Virtual population pharmacokinetic using physiologically based pharmacokinetic model for evaluating bioequivalence of oral lacidipine formulations in dogs |
| title_short | Virtual population pharmacokinetic using physiologically based pharmacokinetic model for evaluating bioequivalence of oral lacidipine formulations in dogs |
| title_sort | virtual population pharmacokinetic using physiologically based pharmacokinetic model for evaluating bioequivalence of oral lacidipine formulations in dogs |
| topic | Physiologically based pharmacokinetic model Virtual population pharmacokinetic Bioequivalence Lacidipine Amorphous solid dispersions |
| url | http://www.sciencedirect.com/science/article/pii/S1818087616300149 |
| work_keys_str_mv | AT binyang virtualpopulationpharmacokineticusingphysiologicallybasedpharmacokineticmodelforevaluatingbioequivalenceoforallacidipineformulationsindogs AT chunnuanwu virtualpopulationpharmacokineticusingphysiologicallybasedpharmacokineticmodelforevaluatingbioequivalenceoforallacidipineformulationsindogs AT binji virtualpopulationpharmacokineticusingphysiologicallybasedpharmacokineticmodelforevaluatingbioequivalenceoforallacidipineformulationsindogs AT mingruiwu virtualpopulationpharmacokineticusingphysiologicallybasedpharmacokineticmodelforevaluatingbioequivalenceoforallacidipineformulationsindogs AT zhongguihe virtualpopulationpharmacokineticusingphysiologicallybasedpharmacokineticmodelforevaluatingbioequivalenceoforallacidipineformulationsindogs AT leishang virtualpopulationpharmacokineticusingphysiologicallybasedpharmacokineticmodelforevaluatingbioequivalenceoforallacidipineformulationsindogs AT jinsun virtualpopulationpharmacokineticusingphysiologicallybasedpharmacokineticmodelforevaluatingbioequivalenceoforallacidipineformulationsindogs |